Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome

Prader-Willi Syndrome Clinical Trial

Official title:

A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02204163
• Other study ID #: LG-HGCL007
• Status: Completed
• Phase: Phase 3
• Start date: June 2014
• Est. completion date: December 2017

Study information

• Verified date: June 2019
• Source: LG Life Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the efficacy and safety after treatment of Eutropin® inj. compared to Genotropin® in infants/toddlers with Prader-Willi syndrome

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

• Inclusion Criteria:

1. Pediatric patients with PWS confirmed by methylation PCR genetic testing

2. Prepubertal pediatric patients (Tanner's Pubertal stage I) at screening

3. Pediatric patients who have never been treated with hGH prior to screening, or who had been treated with hGH for less than 6 months if they had a treatment history, and whose last administration was made 6 months prior to screening

4. Pediatric patients with normal thyroid function at screening (Those with normal function through a hormonal therapy were allowable.)

5. Pediatric patients whose parents or LARs signed the informed consent form in writing after receiving the explanation about the purpose, method, effects, etc. of the clinical study, and who also signed the informed consent form in writing if they are capable of reading and understanding writing.

• Exclusion Criteria:

1. Pediatric patients who are accompanied by other causes for growth retardation as follows except for PWS at screening

: Chronic renal failure (including the case in which renal transplantation has been undergone), Silver-Russell syndrome, Turner's syndrome, Seckel syndrome, Down's syndrome, Noonan syndrome, Cushing's syndrome, congenital infections, psychiatric disorders, chronic debilitating diseases, etc.

2. Pediatric patients with malignancy or a history of malignancy at screening

3. Pediatric patients with severe respiratory disturbance, or sleep apnoea or a history of respiratory infections with an unknown cause at screening. However, those whose condition had been confirmed to be eligible to participate in the clinical study on investigator's judgment were allowed to participae in the study.

4. Pediatric patients with impaired fasting glucose, diabetes, and diabetic retinopathy at screening

5. Pediatric patients whose epiphyses are closed with a growth rate of =1 cm/year at screening

6. Pediatric patients who are being administered any drug that may have an effect on the secretion and actions of hGH (estrogen, androgen, anabolic steroids, corticosteroids, GnRH analogs, thyroxine, aromatase inhibitors, etc.) or anticonvulsants and cyclosporin at screening, and have been administered any of them for a long period of time within 6 months prior to screening (However, those who have been administered a thyroxine preparation for =4 weeks on a stable dose [allowable in case the investigator determines the dose is stable even though it is changeable based upon the weight of the pediatric patient] were allowed to participate in the clinical study.)

7. Pediatric patients who are being administered any drug (e.g. methylphenidate) for treatment of hyperactivity disorders including attention deficit hyperactivity disorder (ADHD) at screening

8. Pediatric patients who are hypersensitive to somatropin or any excipient of the investigational product (cresol or glycerol) or who have a relevant history of hypersensitivity

9. Pediatric patients who have participated in any other clinical studies after enrolled in this study or who had participated in any other clinical studies within 3 months prior to enrollment in this clinical study

10. Pediatric patients in whom this clinical study is considered to be difficult to be conducted for any other reasons on investigator's judgment

Related Conditions & MeSH terms

• Prader-Willi Syndrome
• Syndrome

Intervention

Drug:
• Eutropin

• Genotropin

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Ajou University Hospital	Suwon

Sponsors (1)

Lead Sponsor	Collaborator
LG Life Sciences

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in height SDS (Standard Deviation Score)		baseline and 52 weeks
Primary	Change from baseline in Lean body mass (g)		baseline and 52 weeks
Primary	Change from baseline in Percent body fat (%)		baseline and 52 weeks
Secondary	Change from baseline in height velocity (cm/year)		baseline, 16, 28 and 52 weeks
Secondary	Change from baseline in head circumference (cm)		baseline, 16, 28 and 52 weeks
Secondary	Change from baseline in cognitive development (score) by Bayley Scale		baseline, 28 and 52 weeks
Secondary	Change from baseline in motor development (score) by Bayley Scale		baseline, 28 and 52 weeks
Secondary	Change from baseline in weight SDS		baseline 16, 28 and 52 weeks
Secondary	Change from baseline in BMI (kg/m2) (Body Mass Index)		baseline, 16, 28 and 52 weeks
Secondary	Change from baseline in Bone age (month)		baseline and 52 weeks
Secondary	Change from baseline in Bone mineral density (g/cm)		baseline and 52 weeks
Secondary	Change from baseline in height (cm)		baseline, 16, 28 and 52 weeks
Secondary	Change from baseline in height SDS		baseline, 16 and 28 weeks
Secondary	Change from baseline in IGF-1 (ng/mL) and IGF-1 SDS		baseline, 28, and 52 weeks
Secondary	Change from baseline in IGFBP-3 (ng/mL) and IGFBP-3 SDS		baseline, 28, and 52 weeks